EIF4E and breast cancer: Two recent studies demonstrated that pharmacologic inhibition of eIF4E with ribavirin [26] or inhibition of eIF4E phosphorylation with a multikinase inhibitor that is a potent Mnk1/2 inhibitor, merestinib [72] potently prevented metastasis of highly aggressive mammary cancer 66c14 cells but exhibited modest/no effect on primary tumor growth.